Corcept Therapeutics
CORT
232 hedge funds and large institutions have $1.89B invested in Corcept Therapeutics in 2023 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 86 increasing their positions, 77 reducing their positions, and 41 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
15% more capital invested
Capital invested by funds: $1.65B → $1.89B (+$243M)
12% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 77
4.99% more ownership
Funds ownership: 75.49% → 80.49% (+5%)
4% less funds holding
Funds holding: 241 → 232 (-9)
12% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 41
37% less call options, than puts
Call options by funds: $22.5M | Put options by funds: $36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$50M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$33.9M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$17.4M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$13.9M |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$18.5M |
| 2 |
Man Group
London,
United Kingdom
|
-$15M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.2M |
| 4 |
Renaissance Technologies
New York
|
-$11M |
| 5 |
D.E. Shaw & Co
New York
|
-$8.95M |
CORT Hedge Fund Activity: Q1 2023 in Review
232 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2023, worth a combined $1.89B — up 15% from $1.65B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CORT and 36 opened new positions — a net loss of 5 holders — while 77 trimmed existing stakes and 86 added.
The largest buyer was Millennium Management, adding an estimated $50M. The largest seller was Woodline Partners, exiting entirely with an estimated $18.5M sold.
- 232 institutional investors held Corcept Therapeutics (CORT) as of Q1 2023, down from 241 in Q4 2022.
- Funds reported $1.89B of Corcept Therapeutics stock for Q1 2023, up 15% quarter-over-quarter.
- 36 funds opened new Corcept Therapeutics positions in Q1 2023 and 41 closed out, a net change of -5 holders.
- The largest Corcept Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $50M added.
- The largest Corcept Therapeutics seller in Q1 2023 was Woodline Partners, an estimated $18.5M sold.
Based on aggregated 13F filings for Q1 2023.